Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

EP: 1.An Overview of the ARANOTE Trial

EP: 2.Comparing Trials Studying Treatment Intensification In mHSPC

EP: 3.Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

EP: 4.Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

EP: 5.Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

EP: 6.Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

Now Viewing

EP: 7.Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

EP: 8.Using Ultrasensitive PSA Assays in Routine Practice

EP: 9.The Use of Ultra-Low PSA in Specific Patient Profiles

EP: 10.Selecting Between Receptor Pathway Inhibitors for mHSPC

Future Applications of Ultra-Low PSA Response

Key Themes:

• Potential use of ultra-low PSA response as a clinical trial end point
• Possibility of using PSA response to guide treatment intensification or de-escalation
• Need for further validation of this approach

Expert Insights:

• Dr Shore discussed the potential for ultra-low PSA response to serve as an end point in future clinical trials.

He highlighted how this metric could potentially influence precision medicine approaches while emphasizing the need for further validation.